45 Stocks Moving In Friday’s Mid-Day Session
Gainers
KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2 billion. Guggenheim upgraded KAR Auction Services from Sell to Neutral.
SVB Leerink Maintains Outperform on Macrogenics, Lowers Price Target to $23
SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and lowers the price target from $40 to $23.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
BMO Capital Initiates Coverage On Macrogenics with Outperform Rating, Announces Price Target of $31
BMO Capital analyst Etzer Darout initiates coverage on Macrogenics (NASDAQ:MGNX) with a Outperform rating and announces Price Target of $31.
SMBC Nikko Initiates Coverage On Macrogenics with Outperform Rating, Announces Price Target of $40
SMBC Nikko analyst David Dai initiates coverage on Macrogenics (NASDAQ:MGNX) with a Outperform rating and announces Price Target of $40.
I-Mab Announces IND Approval From China NMPA For Phase 2 Clinical Trial Of Enoblituzumab In Combination With Pembrolizumab In Solid Tumors
I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation